PAVMED INC

PAVM refers to the common stock of PAVmed Inc., a medical technology company listed on the Nasdaq exchange. The ticker PAVM represents equity ownership in a business focused on developing and commercializing medical devices and related healthcare products. As a small-cap stock, PAVM carries the characteristics typical of early-stage medtech companies, including potential for significant volatility and dependence on product development milestones.

The latest price of PAVM stock is displayed in real time on this stock detail page. Because share prices change continuously during market hours, any figure quoted here would quickly become outdated. For accurate and current pricing, refer to the quote panel at the top of this page, which reflects the most recent trade, along with the day's open, high, low, and volume data.

PAVM is a small-cap medtech stock, a category that often experiences significant price swings. Volatility can be driven by clinical trial updates, regulatory decisions, financing news, and changing investor sentiment toward speculative healthcare companies. Investors can assess historical volatility by reviewing PAVM's price chart, beta, and average daily trading volume shown on this page, though past price behavior does not guarantee future movements.

Valuation for PAVM is commonly examined using metrics such as price-to-sales, price-to-book, and enterprise value, since the company may not have consistent positive earnings. Comparing these ratios to peers in the medical device sector can provide context. Investors should also consider cash burn, pipeline progress, and revenue trends rather than relying on a single metric when assessing whether PAVM appears reasonably valued.

PAVM does not currently pay a dividend. The company is a medical technology firm that typically reinvests capital into product development, clinical studies, and commercialization rather than returning cash to shareholders. Any future decision to initiate a dividend would depend on sustained profitability, available cash flow, and board approval. For the most current dividend status, check the dividend section of this stock detail page.

Key risks for PAVM include regulatory hurdles in the medical device approval process, reliance on successful clinical trial outcomes, potential dilution from future capital raises, and competition from larger medtech companies. Additionally, PAVM may face limited revenue diversification and significant cash requirements. These factors can amplify stock price volatility, making it important to review SEC filings and corporate updates for a full picture of company-specific risks.